Anebulo Pharmaceuticals (ANEB) Competitors $2.39 -0.07 (-2.85%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.05 (+2.09%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. ETON, PRTC, CMPS, RGNX, CGEM, PRTA, ITOS, ERAS, REPL, and IVAShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Eton Pharmaceuticals (ETON), PureTech Health (PRTC), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Cullinan Therapeutics (CGEM), Prothena (PRTA), iTeos Therapeutics (ITOS), Erasca (ERAS), Replimune Group (REPL), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors Eton Pharmaceuticals PureTech Health COMPASS Pathways REGENXBIO Cullinan Therapeutics Prothena iTeos Therapeutics Erasca Replimune Group Inventiva Eton Pharmaceuticals (NASDAQ:ETON) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Does the media refer more to ETON or ANEB? In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Anebulo Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.47 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anebulo Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ETON or ANEB? Eton Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500. Do insiders & institutionals hold more shares of ETON or ANEB? 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 16.0% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend ETON or ANEB? Eton Pharmaceuticals presently has a consensus price target of $29.67, suggesting a potential upside of 66.01%. Anebulo Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 130.13%. Given Anebulo Pharmaceuticals' higher probable upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings & valuation, ETON or ANEB? Eton Pharmaceuticals has higher revenue and earnings than Anebulo Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$39.01M12.29-$3.82M-$0.16-111.69Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-9.19 Is ETON or ANEB more profitable? Anebulo Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -7.10%. Eton Pharmaceuticals' return on equity of -0.73% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-7.10% -0.73% -0.22% Anebulo Pharmaceuticals N/A -90.11%-84.53% SummaryEton Pharmaceuticals beats Anebulo Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.07M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E RatioN/A21.0283.0126.65Price / SalesN/A379.56503.05163.66Price / CashN/A43.5325.7028.92Price / Book15.938.1210.796.52Net Income-$8.20M-$53.35M$3.29B$266.21M7 Day Performance-5.16%0.05%0.01%-0.76%1 Month Performance-11.48%7.08%7.06%3.83%1 Year Performance27.13%11.92%50.09%24.39% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals1.9736 of 5 stars$2.39-2.8%$5.50+130.1%+35.9%$101.07MN/A0.004Gap DownETONEton Pharmaceuticals2.579 of 5 stars$17.24+0.9%$29.67+72.1%+279.3%$462.38M$39.01M-107.7520News CoveragePositive NewsPRTCPureTech Health2.3561 of 5 stars$19.36+1.9%$45.00+132.4%-24.8%$461.00M$4.83M0.00100Short Interest ↑Gap DownCMPSCOMPASS Pathways2.4964 of 5 stars$4.79+4.5%$16.29+240.3%-34.8%$459.08MN/A-2.60120News CoverageRGNXREGENXBIO4.3829 of 5 stars$8.98+0.1%$28.38+216.0%-13.1%$455.55M$83.33M-2.62370News CoverageCGEMCullinan Therapeutics2.6878 of 5 stars$7.65+0.1%$26.80+250.3%-58.3%$452.51MN/A-2.3730Positive NewsPRTAProthena3.3413 of 5 stars$8.32-0.7%$30.25+263.6%-60.5%$448.89M$135.16M-1.48130News CoverageAnalyst ForecastITOSiTeos Therapeutics3.5091 of 5 stars$10.14+0.0%$15.50+52.9%N/A$448.07M$35M-2.1790News CoveragePositive NewsShort Interest ↓ERASErasca2.3674 of 5 stars$1.58-0.9%$4.29+172.1%-47.8%$446.78MN/A-3.50120News CoverageAnalyst ForecastREPLReplimune Group4.2285 of 5 stars$5.67+3.2%$7.67+35.3%-42.7%$442.21MN/A-1.75210Trending NewsGap DownIVAInventiva2.742 of 5 stars$4.57-2.1%$10.40+127.6%+148.2%$439.09M$9.20M0.00100News CoverageAnalyst ForecastShort Interest ↑Gap Down Related Companies and Tools Related Companies Eton Pharmaceuticals Alternatives PureTech Health Alternatives COMPASS Pathways Alternatives REGENXBIO Alternatives Cullinan Therapeutics Alternatives Prothena Alternatives iTeos Therapeutics Alternatives Erasca Alternatives Replimune Group Alternatives Inventiva Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANEB Stock Alerts